INTRODUCTION
Requirements for safety and quality of intravenous immunoglobulin G preparations Gunter 3) Hepatitis Delta Virus (HDV) 4) Human Parvovirus 5) Hepatitis C Virus (HCV).
Various virus-inactivation procedures are currently employed for the purpose of optimising the safety of plasma products.
VIRUS INACTIVATION PROCEDURE WITH MIg
Virus removal by Cohn-fractionation, with particular reference to HIV, has already been comprehensively described. '2 The occurrence of HCV infection after IVIg treatment led to safety improvement in the manufacturing procedures.
Virus removal is achieved by the following measures which are employed in addition to the cold ethanol fractionation: 1) Reduction in the pH values to 4-25 with subsequent incubation of the finished preparation at pH 4-25 and 25°C for 24 days 2) Beta-propiolactone treatment 3) Pasteurisation, 10 hours at 60°C 4) Oxidative S-sulphonation 5) Hydrolases bound to fixed phases. 6) Solvent/detergent treatment with TNBP (tri-(n-butyl)-phosphate)/Na-cholat resp.
Tween 80 and sodium cholate. Experience has shown that the chemical or physical virus inactivation procedures employed in the manufacturing process impair the development of the IVIg preparations. As a rule, additional auxiliary substances and stabilisers must then be used to prevent changes in the structure and functional capacity of the individual native antibody molecule and also to prevent a change in the composition of subclasses IgG,q VALIDATION Various studies are performed to validate the viral inactivation potential of a manufacturing process. Such studies consist of testing every single manufacturing step for its viral inactivation potential with regard to a specific virus.
As a rule, a defined quantity of virus is added to the starting material. Test samples are run in duplicates which are treated identically. The respective samples are examined for their viral content at the end of each selected manufacturing step. The value found is then compared with the quantity of virus which was added initially to the starting material.
Model viruses, as well as host-specific Table 3 Example of a reduction through Cohnfractionation Viruses Reduction (log,)
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4) HIV-1
Retrovirus, serves at the same time as a model virus for HIV-2. The data for the elimination rates are expressed logarithmically. The reduction factor is calculated using the following formula: Total amount of virus in the starting material Total amount of virus in the test sample Table 3 shows an example of typical elimination rates using Cohn-fractionation as the sum of the individual manufacturing steps (overall reduction factor).
While the elimination rates of the model virus for HIV and HBV appear to be sufficient, the reduction in HCV and nonenveloped viruses is distinctly lower. It has already been mentioned that due to the unlikely risk of viral infection from IVIg, these preparations have been given little attention. From a current standpoint, however, the introduction of a further manufacturing step for the purpose of viral inactivation-in addition to the viral elimination potential of the Cohn-fractionation procedure-should be made a requirement for the manufacture of IVIg preparations.
It has also been demonstrated that commercial and paid blood donations increase the risk of infection with hepatitis pathogens. It has been shown that infection with hepatitis considerably increases in relation to the number of paid blood donors."3 The EC commission guidelines therefore recommend using unpaid voluntary donors.8 This recommendation also provides a better guarantee of a balanced antibody spectrum of the WIg preparations for a given population.'4
Conclusion
The 1982 WHO requirements form the minimum basis world wide for the quality and safety of IVIg. Because the range of application of IVIg has expanded considerably in the last 10 years, there is a fundamental requirement to introduce further active virus inactivation procedures which supplements the virus elimination achieved with, for example, the Cohn-Oncley-fractionation method.
This applies above all for IVIg preparations which are not obtained from blood and plasma from unpaid voluntary donors in the framework of a national self-supply, since such sources are characterised by a higher risk of infection-particularly when they are collected in social fringe groups of population centres. 13 Because the various active virus inactivation procedures exhibit different specificity of action for certain viruses, an IVIg preparation would be ideal-according to current knowledge-if it were obtained nationally from voluntary, unpaid blood or blood plasma donations and subjected to two active virus elimination procedures with different mechanisms of action.
